<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F257D5A-AA9A-4460-9953-37368441A1EA"><gtr:id>1F257D5A-AA9A-4460-9953-37368441A1EA</gtr:id><gtr:name>University of Calgary</gtr:name><gtr:address><gtr:line1>2500 University Drive</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/395F850A-031E-45AD-817A-4C46D042B92C"><gtr:id>395F850A-031E-45AD-817A-4C46D042B92C</gtr:id><gtr:name>University of Cincinnati</gtr:name><gtr:address><gtr:line1>University of Cincinnati</gtr:line1><gtr:line2>2624 Clifton Avenue</gtr:line2><gtr:postCode>OH 45221-0</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/38604300-D348-417A-994D-AC90FDF777D7"><gtr:id>38604300-D348-417A-994D-AC90FDF777D7</gtr:id><gtr:name>National University of Ireland Galway</gtr:name><gtr:address><gtr:line1>National University of Ireland Galway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Molecular. Genetics &amp; Pop Health</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F257D5A-AA9A-4460-9953-37368441A1EA"><gtr:id>1F257D5A-AA9A-4460-9953-37368441A1EA</gtr:id><gtr:name>University of Calgary</gtr:name><gtr:address><gtr:line1>2500 University Drive</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/395F850A-031E-45AD-817A-4C46D042B92C"><gtr:id>395F850A-031E-45AD-817A-4C46D042B92C</gtr:id><gtr:name>University of Cincinnati</gtr:name><gtr:address><gtr:line1>University of Cincinnati</gtr:line1><gtr:line2>2624 Clifton Avenue</gtr:line2><gtr:postCode>OH 45221-0</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/38604300-D348-417A-994D-AC90FDF777D7"><gtr:id>38604300-D348-417A-994D-AC90FDF777D7</gtr:id><gtr:name>National University of Ireland Galway</gtr:name><gtr:address><gtr:line1>National University of Ireland Galway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9DB71E5D-F59A-48C9-9A38-20594C65AD77"><gtr:id>9DB71E5D-F59A-48C9-9A38-20594C65AD77</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Sandercock</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E39CE527-46D3-468D-B0BC-211FFEA92153"><gtr:id>E39CE527-46D3-468D-B0BC-211FFEA92153</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Dennis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/070AF2F0-F5AE-4A96-B29B-FE72A23E1FF5"><gtr:id>070AF2F0-F5AE-4A96-B29B-FE72A23E1FF5</gtr:id><gtr:firstName>Joanna</gtr:firstName><gtr:surname>Wardlaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400069"><gtr:id>A694EBDF-EB6C-475B-9940-C32EB30E8092</gtr:id><gtr:title>Third International Stroke Trial: IST-3</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400069</gtr:grantReference><gtr:abstractText>Strokes are a major cause of disability. Most strokes are due a blood clot blocking an artery in the brain. We know that the ?clot busting? drug rt-PA, given to a person with a stroke within the first 2 or 3 hours of start of the symptoms, can improve their chances of both being alive and not being disabled from the stroke. 
But, we know much less about the benefits in older people and in people who only get to hospital more than 3 hours after the symptoms began. 
To find out if more patients with stroke could benefit from this treatment, we are a performing a clinical trial. It will involve several thousand people from around the world. Patients who recognise that their symptoms could be a stroke and get to hospital quickly enough will be asked to help with the study. 
If the study establishes that a wider variety of patients can be treated, millions of people with stroke worldwide could benefit.</gtr:abstractText><gtr:technicalSummary>IST-3 is an international, multi-centre, randomised, controlled trial of iv rt-PA (0.9 mg/kg) within 6 hours of onset of acute ischaemic stroke. All potential patients must be assessed and have brain imaging without delay. CT scanning is the prime imaging modality, but CT perfusion/ CT angiography, MRI DWI/PWI/angiography and transcranial doppler can be used as additional selection criteria in centres which participate in the IST3 imaging substudy. Patients who meet clinical and brain imaging criteria are entered by means of a telephone call to a fast centralised computer system which records baseline data, balances on key prognostic factors and allocates treatment. Follow-up is conducted by postal or telephone questionnaire, independently of the clinician treating the patient. The primary measure of outcome is the proportion of patients who are dead or dependent at six months (poor functional outcome). The trial involves innovative methods to make a large scale trial feasible. The web-based CT reading tool developed in the start-up phase is already being applied in several other imaging research projects. The trial builds on our NHS HTA formal economic modelling exercise and will provide reliable evidence on the place of this controversial treatment in routine clinical practice in the NHS (and other publicly funded Health Services). The trial will also provide important - and much needed - randomised trial data on the balance of risk and benefit of this treatment in older people, who have been deliberately excluded from earlier trials of thrombolysis.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3274637</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>IST-3 UK, Norway and Sweden long-term survival study</gtr:description><gtr:id>B423C262-5AEA-4E37-A3CB-F77A3935AFC1</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>56b37753d6ac33.64274906-4</gtr:outcomeId><gtr:partnerContribution>Continuing follow-up and collection of resource use data</gtr:partnerContribution><gtr:piContribution>Set up an ran the IST-3 trial, support to recruit and perform early follow-up in these 3 countries</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC/Cancer Research UK/BHF Clinical Trial Service Unit &amp; Epidemiological Studies Unit</gtr:department><gtr:description>Stroke Thrombolysis Trialists Collaboration</gtr:description><gtr:id>EC0078C4-2193-4867-9381-B314C3E1EC14</gtr:id><gtr:impact>publications planned for 2013</gtr:impact><gtr:outcomeId>nHLPQcxpeTF-2</gtr:outcomeId><gtr:partnerContribution>Vacsular Overviews Group, University of Oxford provided statistical and data mangement and administrative support.
Boehringer Ingelheim provided data from each of thier trials of rt-PA fro stroke</gtr:partnerContribution><gtr:piContribution>We have contributed a subset of the IST-3 trial data</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>IST-3 UK, Norway and Sweden long-term survival study</gtr:description><gtr:id>0B689B25-929E-4096-B95D-2AEC96797A10</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>56b37753d6ac33.64274906-3</gtr:outcomeId><gtr:partnerContribution>Continuing follow-up and collection of resource use data</gtr:partnerContribution><gtr:piContribution>Set up an ran the IST-3 trial, support to recruit and perform early follow-up in these 3 countries</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National University of Ireland, Galway (NUI)</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>IST-3 UK, Norway and Sweden long-term survival study</gtr:description><gtr:id>E72A54FD-FB87-4D01-8667-01C272A1677D</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>56b37753d6ac33.64274906-2</gtr:outcomeId><gtr:partnerContribution>Continuing follow-up and collection of resource use data</gtr:partnerContribution><gtr:piContribution>Set up an ran the IST-3 trial, support to recruit and perform early follow-up in these 3 countries</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boehringer Ingelheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>MRC Neurogrid</gtr:description><gtr:id>376B144C-240E-40A3-B642-D2B9D7EBFE83</gtr:id><gtr:impact>Publications and demonstration meetings meetings 18705995</gtr:impact><gtr:outcomeId>147C989F839-1</gtr:outcomeId><gtr:piContribution>We provided stroke image data and developed the stroke ontology</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Calgary</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Division of Neurology</gtr:department><gtr:description>TEMPO-2</gtr:description><gtr:id>C98836B2-CC8F-4AA1-9EE3-22FF4B0E4D80</gtr:id><gtr:impact>Conference platform presentation 2014 and associated published abstract (see publications)</gtr:impact><gtr:outcomeId>56b3745aa623e6.52430613-1</gtr:outcomeId><gtr:partnerContribution>Made a platform presentation and published an abstract of the analyses, cited the results in the the TEMPO-2 trial protocol</gtr:partnerContribution><gtr:piContribution>We shared IST-3 data to enable planning of a new trial in mild stroke</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Health Economics Research Centre</gtr:department><gtr:description>IST-3 UK, Norway and Sweden long-term survival study</gtr:description><gtr:id>79B6587E-AF2D-4402-AC1E-934D62D1EFA6</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>56b37753d6ac33.64274906-1</gtr:outcomeId><gtr:partnerContribution>Continuing follow-up and collection of resource use data</gtr:partnerContribution><gtr:piContribution>Set up an ran the IST-3 trial, support to recruit and perform early follow-up in these 3 countries</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cincinnati</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>PRISMS trial group</gtr:description><gtr:id>86C809FF-D011-4192-A741-BD13FF3908EC</gtr:id><gtr:impact>Publication to date listed under publications</gtr:impact><gtr:outcomeId>56b0b5c9467442.49905038-1</gtr:outcomeId><gtr:partnerContribution>Publication of papers making use of the data we provided</gtr:partnerContribution><gtr:piContribution>Data shared to allow planning of a new trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>MRC Neurogrid</gtr:description><gtr:id>4E59AC5F-A454-4E17-8F8F-18D4ADBC6CC8</gtr:id><gtr:impact>IST-3 image data management improved. Ontology being used for multicentre/multinational image collaboration in stroke perfusion imaging (STIR) for which funding being sought. Ontology being used in SINAPSE/IST-3 collaboration image data reporting. Ontology will be used as framework for archiving IST3 trial clinical, imaging data and other relevant meta-data and facilitate open access to the trial dataset once the main analyses are published 18705995</gtr:impact><gtr:outcomeId>AA7EAFA4A87-1</gtr:outcomeId><gtr:partnerContribution>Ontology for stroke Intellectual imput to clarify stroke lesions in scans Stroke multicentre trial scan management</gtr:partnerContribution><gtr:piContribution>Developed ontology for stroke CT and MR scan meta data (paper under review). Developed image viewing/searching tool for large image datasets. Gained substantial experience of differences between stroke, psychosis, dementia in terms of metadata and image analysis and image data management requirements.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial College Trust</gtr:department><gtr:description>CT scan reading and machine learning</gtr:description><gtr:id>52DBBBEC-7B52-432A-B233-A219DF30FA5E</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56b375bd7348f2.74322229-1</gtr:outcomeId><gtr:partnerContribution>Technician to do the work and validate the algorithm. This collaboration helps build our skills in curating and sharing image repositories and in automated analysis of brain scans</gtr:partnerContribution><gtr:piContribution>Enabled team from Imperial to have access to IST-3 scan files in DICOM format to permit analysis by machine learning algorithm.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MHRA review of market authorisation for alteplase</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>031A1617-9B3A-4110-85F4-962EB62BA09F</gtr:id><gtr:impact>Presentation of IST-e3 results to the expert panel convened by MHRA</gtr:impact><gtr:outcomeId>589b3964b1c2c7.83891823</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stroke Research Network Meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1DE30DA3-D20F-4D98-9B23-C0808EA00D58</gtr:id><gtr:impact>As part of the Stroke Research Network Porfolio of trials IST-3 has been presented at all Stroke Research Network Meetings in the UK.

This has raised the profile of the trial in the UK and helped to raise awareness of thrombolysis as a treatment for stroke and raise awareness of the trial to a much wider audience (Chest, Heart &amp;amp; Stroke, Stroke Association) and members of the public. This has resulted in the UK providing the majority of recruitment into the trial to date.</gtr:impact><gtr:outcomeId>P9U3oCSspP3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4041</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chest Heart and Stroke Small Grants</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Chest Heart &amp; Stroke Scotland</gtr:fundingOrg><gtr:id>0BF2DACA-45E9-49B3-9D08-6222E5E5700C</gtr:id><gtr:outcomeId>56d85597b77642.66087778</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>264000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy and Mechanism Evaluation Programme</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>57490290-6C7C-486C-AF31-5645C472AB4C</gtr:id><gtr:outcomeId>77B100FB2EF0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MHRA expert review of alteplase for stroke</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>3E169367-437D-454A-A06B-E6D0AB928DA1</gtr:id><gtr:impact>In view of concerns expressed about the integrity of the trial data and the safety of treatment the MHRA undertook a review of the market authorisation for the use of alteplase for the treatment of acute ischaemic stroke. The review included careful review of the IST-3 data and the the MHRA requested additional analyses from the IST-3 group. As a result of this review, the MHRA saw no reason to modify the market authorisation, except that - in the light of the IST3 results showing benefit in this age category - it made a strong recommendation to the Market Authorisation Holder, Boehringer Ingelheim, to submit an application to remove the current contraindication of age &amp;gt; 80 years on the authorisation. This will be of benefit to elderly patients presenting with stroke worldwide.</gtr:impact><gtr:outcomeId>56b371c5df1228.41450988</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Change to National Guideline for stroke</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>UK intercollegiate Guideline on stroke</gtr:guidelineTitle><gtr:id>06ACD025-73A3-4C68-B378-34A9F89F6A1C</gtr:id><gtr:impact>Greater use of thrombolysis in the elderly</gtr:impact><gtr:outcomeId>6F8CE415B0B</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>https://www.rcplondon.ac.uk/guidelines-policy/stroke-guidelines</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>PRISMS Clinical trial in USA underway, funded by Genetech</gtr:description><gtr:id>241D8BD2-EC63-4EE7-A3EE-60EDBA9452DC</gtr:id><gtr:impact>data sharing enabled a new clinical trial to be funded</gtr:impact><gtr:outcomeId>56b0bac1124139.22234355</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>alteplase for mild ischaemic stroke</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The IST-3 trial is a large-scale randomised controlled trial of intravenous thrombolytic therapy with the drug Alteplase. The dataset comprises a number of files describing the IST-3 dataset, and information about how to apply to the study investigators for access to the raw patient-level data.</gtr:description><gtr:id>A4212324-1B5D-491A-94D4-F2A163E4FD64</gtr:id><gtr:impact>the publications of the STTC (see publication list), with impact on MHRA review of market authorisation for stroke, and on international stroke guidelines</gtr:impact><gtr:outcomeId>56b0b8ffaab3f8.85992378</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IST-3 dataset</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://datashare.is.ed.ac.uk/</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4AB879C4-581C-4B03-8F1F-535A2912EE1F</gtr:id><gtr:title>Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>589b34546794c8.19854997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7D44D8A-B406-4C61-8608-5A99E624D0E9</gtr:id><gtr:title>Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53eb0e856a7f3b3e6ce1c14558548cda"><gtr:id>53eb0e856a7f3b3e6ce1c14558548cda</gtr:id><gtr:otherNames>Lindley RI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>5675dee138908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C107B36-D404-4247-8521-1A485A5EE42D</gtr:id><gtr:title>Imaging perfusion deficits, arterial patency and thrombolysis safety and efficacy in acute ischaemic stroke. Anobservational study of the effect of advanced imaging methods in The Third International Stroke Trial (IST-3), arandomised controlled trial</gtr:title><gtr:parentPublicationTitle>Efficacy and Mechanism Evaluation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e11714bd1c9aada99bb5a4f672013b"><gtr:id>54e11714bd1c9aada99bb5a4f672013b</gtr:id><gtr:otherNames>Wardlaw J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56b0bda0835939.72683563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4353276-B69E-4FA6-B45F-A0F80F03C292</gtr:id><gtr:title>Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12c7afbed82d8caa4bccf507dbc328ea"><gtr:id>12c7afbed82d8caa4bccf507dbc328ea</gtr:id><gtr:otherNames>IST-3 collaborative group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56b099ee4f0a69.68453148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DCF1A50-8DFA-4F8E-BA87-04CEE232DDCD</gtr:id><gtr:title>Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>589b3602ce7652.31693269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2382E08A-A8C2-4D06-9778-13547FEF2336</gtr:id><gtr:title>Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>5675dc93a757d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7CBEAF9-244E-4FB7-B427-ED7078482C00</gtr:id><gtr:title>IST-3 stroke trial data available.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>589b3454297e25.64759280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3323549E-1FB4-4EEC-BA7A-F8C7597B4008</gtr:id><gtr:title>Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00ab49571f031de743ed7cffc95455ea"><gtr:id>00ab49571f031de743ed7cffc95455ea</gtr:id><gtr:otherNames>Hacke W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>5a7c458ddcb050.26459281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>024607D2-AC24-4A96-BFE5-8D098E4BA681</gtr:id><gtr:title>Alteplase for ischaemic stroke--responses.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>543c3b7b6d1a96.16125379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F9031CA-93C6-4E1F-A807-E288841ABC7B</gtr:id><gtr:title>Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da90cc45e04dfc83bfec5febb3041423"><gtr:id>da90cc45e04dfc83bfec5febb3041423</gtr:id><gtr:otherNames>Stroke Thrombolysis Trialists' Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>56b095c46061e2.57248706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DCB985A-BBE6-4084-A015-71D43E1CC9BA</gtr:id><gtr:title>Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d4944da6060d033e7b78eb9c8749e1"><gtr:id>a6d4944da6060d033e7b78eb9c8749e1</gtr:id><gtr:otherNames>Wardlaw JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_13118_28_22632907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0F4CC98-6245-40CD-A855-BE0E5B52465C</gtr:id><gtr:title>The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?</gtr:title><gtr:parentPublicationTitle>Neurologia i neurochirurgia polska</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aaeccb0fffdfde7ea31e08743c53915"><gtr:id>1aaeccb0fffdfde7ea31e08743c53915</gtr:id><gtr:otherNames>Czlonkowska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3843</gtr:issn><gtr:outcomeId>kJRjijQMvct</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBCBA22A-97BC-43BC-9F7F-2DA422B96436</gtr:id><gtr:title>Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98b47949dc25214a504ac60176dd6163"><gtr:id>98b47949dc25214a504ac60176dd6163</gtr:id><gtr:otherNames>Khatri P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>56b098a75804b2.79264619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A779079-FB06-4492-84D0-D48D937FCB9D</gtr:id><gtr:title>Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d92ef546ea273952a7cfddeb17749e"><gtr:id>27d92ef546ea273952a7cfddeb17749e</gtr:id><gtr:otherNames>Emberson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>543c3b7ba36872.88427276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1DDA62F-DE45-44B5-94D2-2B2469932BBF</gtr:id><gtr:title>Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13118_28_22129158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96F17D7C-7486-4A25-BDD2-60C4679C72D2</gtr:id><gtr:title>Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial).</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1d58113d322c667ad72fb99e454ec27"><gtr:id>d1d58113d322c667ad72fb99e454ec27</gtr:id><gtr:otherNames>Sposato LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>589b37e5d31a64.57843621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>275FECD5-C9BB-41AE-A917-9A14489D784F</gtr:id><gtr:title>Response to letter regarding article, &amp;quot;Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_540e139e139a60a4e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D334D1AD-A1D1-4562-BD0C-AEA28C05F6D0</gtr:id><gtr:title>Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>CCABF114F81</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4139B7F2-9AB5-415B-9EB1-771719E674D7</gtr:id><gtr:title>Effect of thrombolysis in a minor stroke population. Analysis of minor stroke patients treated in the IST-3 study</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd4c49badd92e1afa0608f839b54d95"><gtr:id>3dd4c49badd92e1afa0608f839b54d95</gtr:id><gtr:otherNames>Coutts SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56b36fbccd1b34.08242251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91358415-881F-43A0-8113-AE6757A46E83</gtr:id><gtr:title>Third international stroke trial.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>052A38BA6A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B16980F-44EE-4D99-8BD1-73008236A387</gtr:id><gtr:title>Developing an Integrated Image Bank and Metadata for Large-scale Research in Cerebrovascular Disease: Our Experience from the Stroke Image Bank Project</gtr:title><gtr:parentPublicationTitle>Frontiers in ICT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ed6f525b0f7215ad5ec0c55b5e03b04"><gtr:id>8ed6f525b0f7215ad5ec0c55b5e03b04</gtr:id><gtr:otherNames>Danso S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5a7c4663e0d3e8.28182051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C55BBB7-48B0-4FEA-8106-5F644E67BE77</gtr:id><gtr:title>Cerebral White Matter Hypoperfusion Increases with Small-Vessel Disease Burden. Data From the Third International Stroke Trial.</gtr:title><gtr:parentPublicationTitle>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6706b9ff36bf64dcde43973a3a0b3606"><gtr:id>6706b9ff36bf64dcde43973a3a0b3606</gtr:id><gtr:otherNames>Arba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1052-3057</gtr:issn><gtr:outcomeId>5a7c46023185b4.14189971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37BD561A-374B-423D-93E4-C3BC18A98F3C</gtr:id><gtr:title>Impact of stroke syndrome and stroke severity on the process of consent in the Third International Stroke Trial.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09ee5f196fe0251f050ceb1bd2bfb032"><gtr:id>09ee5f196fe0251f050ceb1bd2bfb032</gtr:id><gtr:otherNames>Kane I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>F26E62A3C68</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCF9BFEC-DE9D-4EEB-9371-1673AE377CCF</gtr:id><gtr:title>How many patients might receive thrombolytic therapy in the light of the ECASS-3 and IST-3 data?</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66decab834dd1b016049f8488474aa28"><gtr:id>66decab834dd1b016049f8488474aa28</gtr:id><gtr:otherNames>Bembenek J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>iSejQ8HSNEu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6665C491-3CCF-4B12-8F7F-2F085DBD7698</gtr:id><gtr:title>Third International Stroke Trial 3: an update.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5740e0d02c059185c681bdec8019e4c1"><gtr:id>5740e0d02c059185c681bdec8019e4c1</gtr:id><gtr:otherNames>Arauz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>56b0becbd769e5.95406321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6FF52B3-2D0D-47B6-9748-C843DFBBCA13</gtr:id><gtr:title>EPITHET--where next?</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>E37777F51CE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA6DA26E-635C-4E19-BEC6-472A702B5235</gtr:id><gtr:title>Acute Stroke Imaging Research Roadmap II.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1b53b7854ba970d986d1d45a71a338b"><gtr:id>f1b53b7854ba970d986d1d45a71a338b</gtr:id><gtr:otherNames>Wintermark M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>589b37e63cd940.70982264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>848A637E-3FD2-4B6A-B09A-9BB355F1B230</gtr:id><gtr:title>Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3).</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14b35526aca38d5dc802104a1608a87"><gtr:id>c14b35526aca38d5dc802104a1608a87</gtr:id><gtr:otherNames>SCOPE (Stroke Complications and Outcomes Prediction Engine) Collaborations</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>24B9F855E35</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45555D10-44FB-4DEE-89D1-2AAE9D4B15E3</gtr:id><gtr:title>Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8f84cffa8d60c2e0b79feeafd6061b"><gtr:id>6e8f84cffa8d60c2e0b79feeafd6061b</gtr:id><gtr:otherNames>Mair G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>589b37e619d687.28983285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8B4285C-173E-44AA-9344-1AC9ABF00D6A</gtr:id><gtr:title>Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f53abbd2857ddb15bd313e00c73cef5"><gtr:id>7f53abbd2857ddb15bd313e00c73cef5</gtr:id><gtr:otherNames>Lees KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>589b3602a18de0.86207742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BEC03D0-38F3-444D-8647-6985875AD7BA</gtr:id><gtr:title>'Where are we now with intravenous thrombolysis for acute ischaemic stroke'?</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>MfuyfwoBft9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68E3A8D0-1EAC-4BC2-80DA-23659AD777E7</gtr:id><gtr:title>Blood pressure variability and leukoaraiosis in acute ischemic stroke.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9986646605b05f3c62cd092e5032434b"><gtr:id>9986646605b05f3c62cd092e5032434b</gtr:id><gtr:otherNames>Dickie DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>5a7c42f865ed27.73938396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C4CEACC-7F2A-441E-A726-50357602002F</gtr:id><gtr:title>Sensitivity and specificity of the hyperdense artery sign for arterial obstruction in acute ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8f84cffa8d60c2e0b79feeafd6061b"><gtr:id>6e8f84cffa8d60c2e0b79feeafd6061b</gtr:id><gtr:otherNames>Mair G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>56b098a7860505.31193405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5346A2A2-00AB-4F3B-A8D6-94CE5825EF15</gtr:id><gtr:title>The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12c7afbed82d8caa4bccf507dbc328ea"><gtr:id>12c7afbed82d8caa4bccf507dbc328ea</gtr:id><gtr:otherNames>IST-3 collaborative group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_13118_28_22632908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D502D4E6-6FDC-43BC-9CA7-F7418B0394A7</gtr:id><gtr:title>Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_540e139e1399c4e07</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56045082-DE65-41A0-B5D9-404BEF1E1CCF</gtr:id><gtr:title>Observer reliability of CT angiography in the assessment of acute ischaemic stroke: data from the Third International Stroke Trial.</gtr:title><gtr:parentPublicationTitle>Neuroradiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8f84cffa8d60c2e0b79feeafd6061b"><gtr:id>6e8f84cffa8d60c2e0b79feeafd6061b</gtr:id><gtr:otherNames>Mair G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3940</gtr:issn><gtr:outcomeId>543c3b7b2b84c0.26309929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B1E6105-4A03-4B0F-BBF2-1062AC73B390</gtr:id><gtr:title>Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_13118_28_22996959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF41C952-4C5B-457F-8273-55C5E7D68290</gtr:id><gtr:title>The NeuroGrid stroke exemplar clinical trial protocol.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d4944da6060d033e7b78eb9c8749e1"><gtr:id>a6d4944da6060d033e7b78eb9c8749e1</gtr:id><gtr:otherNames>Wardlaw JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>F47816C9809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB8CB871-2253-4C66-BD46-DE6A14CED25D</gtr:id><gtr:title>Oxfordshire community stroke project clinical stroke syndrome and appearances of tissue and vascular lesions on pretreatment ct in hyperacute ischemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3).</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33342a95a5440ee213f0804af9129157"><gtr:id>33342a95a5440ee213f0804af9129157</gtr:id><gtr:otherNames>Kobayashi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>955B35AF00A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1BFC0B9-1DF0-4F4B-BAD9-6F3D2A263D93</gtr:id><gtr:title>Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d4944da6060d033e7b78eb9c8749e1"><gtr:id>a6d4944da6060d033e7b78eb9c8749e1</gtr:id><gtr:otherNames>Wardlaw JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>pm_13118_28_23336348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D270104E-429B-462C-854C-6C50A37CC88E</gtr:id><gtr:title>Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8f84cffa8d60c2e0b79feeafd6061b"><gtr:id>6e8f84cffa8d60c2e0b79feeafd6061b</gtr:id><gtr:otherNames>Mair G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b098a72d9e54.70218816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>636F8A33-6FDB-41F8-8B74-0013441EDF5D</gtr:id><gtr:title>Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12c7afbed82d8caa4bccf507dbc328ea"><gtr:id>12c7afbed82d8caa4bccf507dbc328ea</gtr:id><gtr:otherNames>IST-3 collaborative group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_13118_28_23791822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3953E734-B48C-46C8-A15D-E57E46EA9974</gtr:id><gtr:title>Effect of X-Ray Attenuation of Arterial Obstructions on Intravenous Thrombolysis and Outcome after Ischemic Stroke.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8f84cffa8d60c2e0b79feeafd6061b"><gtr:id>6e8f84cffa8d60c2e0b79feeafd6061b</gtr:id><gtr:otherNames>Mair G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d5489b35390.27816287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A722631-5044-4D0B-B030-7830F5766667</gtr:id><gtr:title>Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/889459a7ee599cec60bedb06624900f0"><gtr:id>889459a7ee599cec60bedb06624900f0</gtr:id><gtr:otherNames>Berge E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>56b098a6d9c295.46912387</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400069</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>